Cisplatino Hikma 1mg/ml concentrato per soluzione per infusione

DRUG2 trials

Sponsors

Fondazione Ricerca Traslazionale, Humanitas Mirasole S.p.A.

Conditions

Recurrent Metastatic Nasopharingeal Carcinomastage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Neoadjuvant chemo-immunotherapy for stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

RecruitingCTIS2024-519205-35-01

Fondazione Ricerca Traslazionalestage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

Start: 2025-07-08Target: 30Updated: 2025-09-10

Phase 3

Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population

Not yet recruitingCTIS2025-522472-85-00

Humanitas Mirasole S.p.A.Recurrent Metastatic Nasopharingeal Carcinoma

Target: 49Updated: 2026-01-08